Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 1, 2006, Pages 81-88

  Tauchmanova L ^a   De Simone, G ^a   Musella, T ^a   Orio, F ^a   Ricci, P ^a   Nappi, C ^a   Lombardi, G ^a   Colao, A ^a   Rotoli, B ^a   Selleri, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Allogeneic stem cell plant; Hormone repalcement theraphy; Osteoporosis; Risedronate; Zoledronate

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ESTRADIOL; HYDROXYPROLINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BODY MASS; BONE DENSITY; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FEMUR; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HYDROXYPROLINE URINE LEVEL; HYPERTHERMIA; HYPOGONADISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; SURVIVAL TIME; URINARY EXCRETION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LYMPHOPROLIFERATIVE DISORDERS; OSTEOPOROSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 31344449306     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705196     Document Type: Article

References (44)

1. Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: Effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23: 355-361.
2. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: A prospective study. Biol Blood Marrow Transplant 2001; 7: 257-264.
3. Tauchmanovà L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G et al. Long-lasting bone damage detected by dual energy x-ray absorptiometry, phalangeal osteosonogrammetry and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002; 87: 5058-5065.
4. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: Long-term follow-up of a prospective study. Br J Haematol 2003; 121: 462-468.
5. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: Clinical aspects. Biol Blood Marrow Transplant 2000; 6: 175-181.
6. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 165-171.
7. Schulte CMS, Beelen DW. Bone loss following hematopoietic stem cell transplantation: A long-term follow-up. Blood 2004; 103: 3635-3643.
8. Brennan BMD, Shalet SM. Endocrine late effects after bone marrow transplant (Review). Br J Haematol 2002; 118: 58-66.
9. Chatterjee R, Kottaridis PD. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies (Mini-review). Bone Marrow Transplant 2002; 30: 629-635.
10. Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Di Somma C, Orio F et al. Gonadal status in reproductive age women after allogeneic or autologous stem cell transplantation. Hum Reprod 2003; 18: 1410-1416.
11. Castelo-Branco C, Rovira M, Pons F, Duran M, Sierra J, Vives A et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996; 23: 307-312.
12. Tauchmanovà L, Selleri C, Esposito M, Di Somma C, Orio Jr F, Bifulco G et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporosis Int 2003; 14: 1013-1019.
13. Tauchmanovà L, Ricci P, Serio B, Colao A, Lombardi G, Rotoli B et al. Effect of intravenous zoledronic acid administration in patients with low bone mineral density and/or fast bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005; 90: 627-634.
14. Marcus R, Wong M, Heath III H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16-37.
15. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 8: 2018-2026.
16. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
17. Cohen D, Adachi JD. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 2004; 88: 337-349.
18. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215.
19. del Puente A, Heyse SP, Mandes MG, Mantova D, Carpinelli A, Nutile G et al. Epidemiology of osteoporosis in women in southern Italy. Aging Clin Exp Res 1998; 10: 53-58.
20. Minne HW, Leidig G, Wüster C, Siromachkostov L, Baldauf G, Sauer P et al. A newly defined spine deformity index (SDI) to quantitative vertebral crush fractures in patients with osteoporosis. Bone Miner J 1988; 3: 335-349.
21. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, WHO: Geneve 1994.
22. Massenkeil G, Fiene C, Rosan O, Michael R, Reisinger W, Arnold R. Loss of bone mass and vitamin D deficiency after hematopoetic stem cell transplantation: Standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001; 15: 1701-1705.
23. Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: A mechanism for post-bone marrow transplantation osteopenia. Cancer 2001; 92: 2419-2428.
24. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 2002; 87: 329-335.
25. Stern JM, Chesnut III CH, Bruemmer B, Sullivan KM, Lenssen PS, Aker SN et al. Bone density during treatment of chronic GVHD. Bone Marrow Transplant 1996; 17: 395-400.
26. Balleari E, Garre S, Van Lint MT, Spinelli S, Chiodi S, Repetto E et al. Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignancies. Ann NY Acad Sci 2002; 966: 187-192.
27. Chatterjee R, Kottaridis PD. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for hematological malignancies. Bone Marrow Transplant 2002; 30: 629-635.
28. Okolicsanyi L, Dal Bo N. The gastrointestinal tolerability of bisphosphonates. Aging Clin Exp Res 2001; 13: 344-346.
29. Adami S, Zamberlan N. Adverse effects of bisphosphonates - a comparative review. Drug Safety 1996; 14: 158-170.
30. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661.
31. Boutsen Y, Jamart J, Essenlinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16: 104-112.
32. Selander K, Lehenkari P, Väänänen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994; 55: 368-375.
33. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996; 11: 1482-1491.
34. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoblast to induce caspase cleavage of Mst1 kinase during apoptosis. J Biol Chem 1999; 274: 34967-34973.
35. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000; 60: 6001-6007.
36. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002; 25: 539-546.
37. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-1374.
38. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998; 22: 455-461.
39. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004; 25: 4105-4115.
40. Frediani B, Spreafico A, Capperucci C, Chellini F, Gambera D, Ferrata P et al. Long-term effects of neridronate on human osteoblastic cell cultures. Bone 2004; 35: 859-869.
41. Galotto M, Berisso G, Delfino L, Podestà M, Ottagio L, Dallorso S et al. Stromal damage as consequence of high dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999; 27: 1460-1466.
42. Tauchmanovà L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lomardi G et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: A single center experience and a review. Cancer 2003; 97: 2453-2461.
43. Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2002; 2: 62-67.
44. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130-1136.